As of 2026-03-30, the Intrinsic Value of Rocket Pharmaceuticals Inc (RCKT) is -10.28 USD. This RCKT valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.77 USD, the upside of Rocket Pharmaceuticals Inc is -372.56%.
Based on its market price of 3.77 USD and our intrinsic valuation, Rocket Pharmaceuticals Inc (RCKT) is overvalued by 372.56%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -10.28 - -10.28 | -10.28 | -372.56% |
| P/E | (37.44) - (43.44) | (40.69) | -1179.3% |
| DDM - Stable | (30.61) - (482.92) | (256.77) | -6910.8% |
| DDM - Multi | (0.74) - (8.98) | (1.37) | -136.2% |
| Market Cap (mil) | 409.31 |
| Beta | 1.66 |
| Outstanding shares (mil) | 108.57 |
| Enterprise Value (mil) | 353.02 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.54% |
| Cost of Debt | 5.00% |
| WACC | 6.40% |